| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 6 Feb 2025 | 1 Feb 2025 |
| Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 inter alia to consider and approve approval of Un-audited Financial Results for the quarter and nine months ended 31st December 2024. Respected Sir/Madam, In terms of Regulation 30 and 33 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company in its meeting held today i.e. 6th February, 2025 has inter-alia considered and approved the following: (As per BSE Announcement Dated on 06/02/2025) | ||
| Board Meeting | 9 Nov 2024 | 5 Nov 2024 |
| Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2024 inter alia to consider and approve the Un-audited (Standalone & Consolidated) Financial Results for the quarter and half year ended on 30th September 2024. Outcome of Board Meeting (As Per BSE Announcement Dated on: 09/11/2024) | ||
| Board Meeting | 24 Aug 2024 | 21 Aug 2024 |
| Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/08/2024 inter alia to consider and approve the Un-audited (Standalone & Consolidated) Financial Results for the quarter ended 30th June 2024. Outcome of Board Meeting (As per BSE Announcement Dated on 24/08/2024) | ||
The organisation is the largest CDMO serving the Indian pharmaceutical industry, with a proven track record and a broad clientele.
The IPO comprised a fresh issue of shares worth ₹680 crore and an offer-for-sale (OFS) of 1.73 crore shares, aggregating ₹1,177 crore.
The IPO consists of a fresh issue of ₹680 crore and an offer for sale (OFS) of up to 1.73 crore shares at a face value of ₹2 each.
On Monday, the business said that it had received ₹829 crore from anchor investors ahead of the public share sale subscription period.
The IPO includes a new issue of 1 Crore shares worth ₹680.00 Crore and an offer for sale of 1.73 Crore shares worth ₹1,176.74 Crore.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
